A revolutionary advancement in breast cancer risk assessment, the Myriad myRisk Hereditary Cancer Test combines genetic information with family history and other clinical factors to determine your patient's risk of developing a future cancer.
Expedited testing for time sensitive procedures
groundbreaking breast cancer risk-prediction tool
Due to insurance coverage and financial assistance 75% of patients pay $0
Would Your Patient's Risk of Developing Another Primary Cancer Affect Your Surgical Recommendation?
"When a patient is diagnosed with breast cancer, genetic testing can't be an afterthought." - Dr. Beth Dupree
Would You Want Information to Help Your Patients Reduce Their Risk of Developing Breast Cancer?
"As a breast surgeon, it's very important to me to know whether a patient carries a gene mutation that increases their risk for breast cancer." - Dr. Paul Baron
Get Started Now
Myriad is the unquestioned industry leader in variant classification and reclassification, employing various methods for variant interpretation in hereditary cancer testing to ensure analytical and interpretive accuracy are ever present, driving the best possible treatment and outcomes.
Myriad’s commitment to deliver accurate variant classifications to patients and their families lasts a lifetime:
riskScore, Myriad’s groundbreaking breast cancer risk prediction tool, provides further clarity of a patient’s risk of developing breast cancer for those who do not have a deleterious mutation.
For eligible patients, you can reduce uncertainty even further. Using clinical risk factors and genetic-markers that have been clinically validated, riskScore provides a woman’s 5-year and remaining lifetime risk for developing breast cancer.
riskScore provides women with 5-year and remaining lifetime risk for developing breast cancer by analyzing more than 80 well-known genetic markers presented at the 2017 American Society of Clinical Oncology (ASCO) meeting and validated in studies involving 17,000 participants.
Myriad is continuing to advance the science of riskScore to increase the number of eligible women.
Testing through Myriad is affordable for your patients due to excellent insurance coverage and financial assistance:
Myriad will process and release samples that meet current NCCN and ASBrS (American Society of Breast Surgeons) recommendations for testing*
The value of using a multi-gene breast cancer panel testing to establish treatment options for diagnosed patients, as well as risk-reduction for family members, can have a profound impact on patient management choices and generational cancer incidence.
That’s why Myriad believes that patients should have testing options within their financial reach. Myriad has a financial assistance program for patients who meet certain financial and medical criteria.
* Some exceptions apply (e.g., government payers)
Online tools and tutorials are available to guide you and your staff through the process, and Myriad customer service representatives are always just a call away when you need immediate support - (800) 469-7423
Starter kits and replacement tests can be ordered online 24 hours a day or over the phone with our Customer Service Team.
Once you send a test to our lab, a replacement kit will be sent to your office automatically, so you’ll always have them on hand.
When you register for a MyriadPro account you can access myRisk STAT results, our priority testing option that expedites turnaround time for patients with breast cancer who have a surgery pending.
Myriad has an easy screening process called myGeneHistory that patients can fill out at home or in your office.
Implementing myGeneHistory into your practice will help you identify which of your patients meet criteria for myRisk testing and can be easily filled out in your practice.
Learn about myGeneHistory's benefits, usage, and how this new tool is a healthcare game-changer!
For information on how to implement myGeneHistory into your practice, fill out the form below.
Discussing genetic testing with your patients is a critical part of the process. It is important that the patient understands why the test is being ordered, how it will be performed, what types of results may be received, and how the results may impact their medical management. Myriad can provide tools and materials to help support patient education and informed consent for hereditary cancer testing. Additionally, Myriad has genetic counselors on staff to answer any questions that you may have as a provider, ensuring you are fully supported to discuss the myRisk test results with your patients.
In providing education and counseling to your patients, Myriad’s Patient Education Tools can guide your discussions on hereditary cancer syndromes. Some patients may find sample family letters helpful for disclosing information to their family members. You can download our sample family letter for the Myriad myRisk test HERE.
myRisk testing can be submitted using either saliva or blood samples, which can be collected in only 2 to 5 minutes.
After sample collection, complete an easy-to use requisition. This process is streamlined if you’re already using Myriad’s MyGeneHistory, which automatically pre-populates the TRF form in your MyriadPro account.
When testing affected patients in cases where turnaround time is critical, you can request myRisk STAT and receive results for the genes related to breast cancer in as quickly as 5 to 12 days. A full myRisk report is then made available once the complete test is resulted.
To order myRisk STAT for a patient with breast cancer:
myRisk test results are usually available within 2 weeks, so it’s easy for your staff to schedule patient follow-up appointments
Test results will be mailed to your office and can also be accessed on your MyriadPro account.
A comprehensive report will be provided for every patient who undergoes a myRisk test—whether their results are positive, negative, or elevated.
If you requested myRisk STAT, you’ll receive a preliminary report in 5 to 12 days after your affected patient’s sample was submitted, followed by the full report.
Every full myRisk report begins with a summary of the test results, including the genetic test result, breast cancer riskScore*, and a clinical history analysis. You will see one or a combination of colored symbols representing those results.
Any specific mutations found will be listed, along with other information including Variants of Uncertain Significance (VUS), a summary of society guidelines to optimize your medical management decisions in the MyRisk Management Tool, and a complete list of the genes tested.
Guides to help you and your patients understand their results are included with each report and available below.
If one of your patient’s variants is reclassified, you’ll receive an updated report with the revised result and myRisk Management Tool.
As a surgeon, you want to provide your patients with the best screening and potential surgical recommendation possible based on their personal risk of developing cancer.
Integrating myRisk into your practice can assist you in providing the best care for your patients. Order your physician guide today.